View in EDS PDF Full Text

Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.

Saved in:
Bibliographic Details
Title: Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Authors: Cannon CP (AUTHOR), Curtis SP (AUTHOR), FitzGerald GA (AUTHOR), Krum H (AUTHOR), Kaur A (AUTHOR), Bolognese JA (AUTHOR), Reicin AS (AUTHOR), Bombardier C (AUTHOR), Weinblatt ME (AUTHOR), van der Heijde D (AUTHOR), Erdmann E (AUTHOR), Laine L (AUTHOR), MEDAL Steering Committee (CORPORATE AUTHOR), Cannon, Christopher P (AUTHOR), Curtis, Sean P (AUTHOR), FitzGerald, Garret A (AUTHOR), Krum, Henry (AUTHOR), Kaur, Amarjot (AUTHOR), Bolognese, James A (AUTHOR), Reicin, Alise S (AUTHOR)
Source: Lancet. 11/18/2006, Vol. 368 Issue 9549, p1771-1781. 11p.
Abstract: Background: Cyclo-oxygenase-2 (COX-2) selective inhibitors have been associated with an increased risk of thrombotic cardiovascular events in placebo-controlled trials, but no clinical trial has been reported with the primary aim of assessing relative cardiovascular risk of these drugs compared with traditional non-steroidal anti-inflammatory drugs (NSAIDs). The MEDAL programme was designed to provide a precise estimate of thrombotic cardiovascular events with the COX-2 selective inhibitor etoricoxib versus the traditional NSAID diclofenac.Methods: We designed a prespecified pooled analysis of data from three trials in which patients with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 mg or 90 mg daily) or diclofenac (150 mg daily). The primary hypothesis stated that etoricoxib is not inferior to diclofenac, defined as an upper boundary of less than 1.30 for the 95% CI of the hazard ratio for thrombotic cardiovascular events in the per-protocol analysis. Intention-to-treat analyses were also done to assess consistency of results. These trials are registered at http://www.clinicaltrials.gov with the numbers NCT00092703, NCT00092742, and NCT00250445.Findings: 34 701 patients (24 913 with osteoarthritis and 9 787 with rheumatoid arthritis) were enrolled. Average treatment duration was 18 months (SD 11.8). 320 patients in the etoricoxib group and 323 in the diclofenac group had thrombotic cardiovascular events, yielding event rates of 1.24 and 1.30 per 100 patient-years and a hazard ratio of 0.95 (95% CI 0.81-1.11) for etoricoxib compared with diclofenac. Rates of upper gastrointestinal clinical events (perforation, bleeding, obstruction, ulcer) were lower with etoricoxib than with diclofenac (0.67 vs 0.97 per 100 patient-years; hazard ratio 0.69 [0.57-0.83]), but the rates of complicated upper gastrointestinal events were similar for etoricoxib (0.30) and diclofenac (0.32).Interpretation: Rates of thrombotic cardiovascular events in patients with arthritis on etoricoxib are similar to those in patients on diclofenac with long-term use of these drugs. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 106113070
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Cannon+CP%22">Cannon CP</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Curtis+SP%22">Curtis SP</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22FitzGerald+GA%22">FitzGerald GA</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Krum+H%22">Krum H</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kaur+A%22">Kaur A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bolognese+JA%22">Bolognese JA</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Reicin+AS%22">Reicin AS</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bombardier+C%22">Bombardier C</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Weinblatt+ME%22">Weinblatt ME</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22van+der+Heijde+D%22">van der Heijde D</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Erdmann+E%22">Erdmann E</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Laine+L%22">Laine L</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22MEDAL+Steering+Committee%22">MEDAL Steering Committee</searchLink> (CORPORATE AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cannon%2C+Christopher+P%22">Cannon, Christopher P</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Curtis%2C+Sean+P%22">Curtis, Sean P</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22FitzGerald%2C+Garret+A%22">FitzGerald, Garret A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Krum%2C+Henry%22">Krum, Henry</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kaur%2C+Amarjot%22">Kaur, Amarjot</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bolognese%2C+James+A%22">Bolognese, James A</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Reicin%2C+Alise+S%22">Reicin, Alise S</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 11/18/2006, Vol. 368 Issue 9549, p1771-1781. 11p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>Cyclo-oxygenase-2 (COX-2) selective inhibitors have been associated with an increased risk of thrombotic cardiovascular events in placebo-controlled trials, but no clinical trial has been reported with the primary aim of assessing relative cardiovascular risk of these drugs compared with traditional non-steroidal anti-inflammatory drugs (NSAIDs). The MEDAL programme was designed to provide a precise estimate of thrombotic cardiovascular events with the COX-2 selective inhibitor etoricoxib versus the traditional NSAID diclofenac.<bold>Methods: </bold>We designed a prespecified pooled analysis of data from three trials in which patients with osteoarthritis or rheumatoid arthritis were randomly assigned to etoricoxib (60 mg or 90 mg daily) or diclofenac (150 mg daily). The primary hypothesis stated that etoricoxib is not inferior to diclofenac, defined as an upper boundary of less than 1.30 for the 95% CI of the hazard ratio for thrombotic cardiovascular events in the per-protocol analysis. Intention-to-treat analyses were also done to assess consistency of results. These trials are registered at http://www.clinicaltrials.gov with the numbers NCT00092703, NCT00092742, and NCT00250445.<bold>Findings: </bold>34 701 patients (24 913 with osteoarthritis and 9 787 with rheumatoid arthritis) were enrolled. Average treatment duration was 18 months (SD 11.8). 320 patients in the etoricoxib group and 323 in the diclofenac group had thrombotic cardiovascular events, yielding event rates of 1.24 and 1.30 per 100 patient-years and a hazard ratio of 0.95 (95% CI 0.81-1.11) for etoricoxib compared with diclofenac. Rates of upper gastrointestinal clinical events (perforation, bleeding, obstruction, ulcer) were lower with etoricoxib than with diclofenac (0.67 vs 0.97 per 100 patient-years; hazard ratio 0.69 [0.57-0.83]), but the rates of complicated upper gastrointestinal events were similar for etoricoxib (0.30) and diclofenac (0.32).<bold>Interpretation: </bold>Rates of thrombotic cardiovascular events in patients with arthritis on etoricoxib are similar to those in patients on diclofenac with long-term use of these drugs. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=106113070
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/s0140-6736(06)69666-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 1771
    Titles:
      – TitleFull: Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cannon CP
      – PersonEntity:
          Name:
            NameFull: Curtis SP
      – PersonEntity:
          Name:
            NameFull: FitzGerald GA
      – PersonEntity:
          Name:
            NameFull: Krum H
      – PersonEntity:
          Name:
            NameFull: Kaur A
      – PersonEntity:
          Name:
            NameFull: Bolognese JA
      – PersonEntity:
          Name:
            NameFull: Reicin AS
      – PersonEntity:
          Name:
            NameFull: Bombardier C
      – PersonEntity:
          Name:
            NameFull: Weinblatt ME
      – PersonEntity:
          Name:
            NameFull: van der Heijde D
      – PersonEntity:
          Name:
            NameFull: Erdmann E
      – PersonEntity:
          Name:
            NameFull: Laine L
      – PersonEntity:
          Name:
            NameFull: MEDAL Steering Committee
      – PersonEntity:
          Name:
            NameFull: Cannon, Christopher P
      – PersonEntity:
          Name:
            NameFull: Curtis, Sean P
      – PersonEntity:
          Name:
            NameFull: FitzGerald, Garret A
      – PersonEntity:
          Name:
            NameFull: Krum, Henry
      – PersonEntity:
          Name:
            NameFull: Kaur, Amarjot
      – PersonEntity:
          Name:
            NameFull: Bolognese, James A
      – PersonEntity:
          Name:
            NameFull: Reicin, Alise S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 11
              Text: 11/18/2006
              Type: published
              Y: 2006
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 368
            – Type: issue
              Value: 9549
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1